Shots:

• The collaboration initially focuses on developing in vitro- functional model of heart failure with HFpEF utilizing Novoheart’s 3-D human ventricular cardiac organoid chamber (hvCOC) technology which reproduces key phenotypic characteristics of HFpEF
• The focus of the collaboration is to combine Novoheart’s hvCOC model with AstraZeneca’s expertise in heart failure to build the gap between in vivo animal models and clinical studies- thus accelerating the discovery process by providing human-specific preclinical data
• Human heart-in-a-jar is the only human-engineered heart tissue available in the market which fabricated with specific cellular & matrix compositions and iPSCs- allowing control over patient’s physical and mechanical properties to mimic observation in HFpEF heart

Click here to­ read full press release/ article 

Ref: GlobeNewswire | Image: AstraZeneca